You are using an older browser version. Please use a supported version for the best MSN experience.

AstraZeneca Signs Deal With Canada to Provide 20 Million Coronavirus Vaccine Doses

The Motley Fool logo The Motley Fool 9/25/2020 Cory Renauer
a blue bag on a table: AstraZeneca Signs Deal With Canada to Provide 20 Million Coronavirus Vaccine Doses © Provided by The Motley Fool AstraZeneca Signs Deal With Canada to Provide 20 Million Coronavirus Vaccine Doses

AstraZeneca (NYSE: AZN) signed a large coronavirus vaccine-delivery deal with Canada on Friday. The big pharmaceutical company will deliver up to 20 million doses of its coronavirus vaccine candidate, AZD1222.

This isn't the first time AstraZeneca has signed a commitment to deliver enormous quantities of its coronavirus vaccine candidate before it's had a chance to prove itself safe and effective in a phase 3 clinical trial. In June, the company agreed to supply Europe with up to 400 million doses of AZD1222 with deliveries beginning by the end of the year. The company also has a deal with Brazil to provide around 30 million finished doses of the vaccine by December.

a blue bag sitting on top of a table: Masks and a COVID-19 vaccine. © Getty Images Masks and a COVID-19 vaccine.

Recently, clinical trials with AZD1222 were paused around the globe after a clinical trial participant in the U.K. experienced an adverse event serious enough to require hospitalization. Following inspections from independent data monitors, phase 3 studies around the globe have been allowed to continue, with the exception of one key location. To date, clinical trials with AZD1222 in the U.S. are still paused.

AZD1222 employs the hollowed-out husk of a different virus to deliver blueprints for portions of SARS-CoV-2, the virus responsible for COVID-19. The viral vector AZD1222 uses can't replicate itself, but there's always a slight chance a significant percentage of the population will have immune systems that overreact to a delivery vehicle that never elicits reactions otherwise

At the moment, there are nine SARS-CoV-2 vaccine candidates in clinical trials, but AZD1222 is arguably in the lead despite its recent hold-up. In late June, AZD1222 became the first experimental vaccine program to begin a phase 3 trial, sponsored by concerned entrepreneurs in Brazil. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

SPONSORED:

10 stocks we like better than AstraZeneca

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AstraZeneca wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of September 24, 2020

 

AdChoices
AdChoices

More from The Motley Fool

The Motley Fool
The Motley Fool
image beaconimage beaconimage beacon